Changes in the primary outcome in Ebola vaccine trial--Authors' reply.

@article{Kieny2016ChangesIT,
  title={Changes in the primary outcome in Ebola vaccine trial--Authors' reply.},
  author={Marie Paule Kieny and Ira M. Longini and Ana-Maria Henao-Restrepo and Conall H. Watson and Matthias Egger and W. John Edmunds},
  journal={Lancet},
  year={2016},
  volume={387 10027},
  pages={1509-10}
}
www.thelancet.com Vol 387 April 9, 2016 1509 Authors’ reply We thank Yanyu Zhang and colleagues for their interest in the methods of Ebola Ça suffit ring vaccination trial in Guinea and for their words of encouragement. In our article published in the British Medical Journal, we specifi ed that the primary analysis in a ring vaccination trial estimates vaccine effi cacy against Ebola virus disease. Vaccine efficacy is defined as VE=1−è, where è=ë1/ë0 is the hazard ratio of ë1 (the hazard of… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 11 times. VIEW TWEETS

From This Paper

Topics from this paper.

References

Publications referenced by this paper.
Showing 1-6 of 6 references

Eff ect of the REG 1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention ( REGULATEPCI ) : a randomised clinical trial

R Mehran, TJ Povsic
Lancet • 2016

Effi cacy and eff ectiveness of an rVSVvectored vaccine expressing Ebola surface glycoprotein : interim results from the Guinea ring vaccination clusterrandomised trial

ME Halloran, IM Longini, CJ Struchiner
Lancet • 2015

Study designs for evaluating diff erent effi cacy and eff ectiveness aspects of vaccines

ME Halloran, CJ Struchiner, IM Longini
Design and analysis of vaccine studies • 2010

Similar Papers

Loading similar papers…